Abvc Biopharma (ABVC) Research & Development (2015 - 2026)

Abvc Biopharma (ABVC) has reported Research & Development for 12 consecutive years, with $22707.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 31.76% year-over-year to $22707.0; the trailing twelve-month figure through Jun 2026 stood at $114755.0 (down 13.03% YoY), and the FY2025 full-year result was $121085.0, down 32.46% from the prior year.
• Research & Development eased to $22707.0 in Q2 2026 per ABVC's latest filing, from $33100.0 in the prior quarter.
• Across five years, Research & Development topped out at $1.5 million in Q4 2022 and bottomed at $22707.0 in Q2 2026.
• Historically, Research & Development has averaged $228474.3 across 5 years, with a median of $54733.5 in 2024.
• The sharpest annual moves came in 2022 and 2023: Research & Development jumped 474.89% in 2022, then plunged 95.17% in 2023.
• Over 5 years, Research & Development stood at $1.5 million in 2022, then slumped by 95.17% to $72185.0 in 2023, then slumped by 55.7% to $31980.0 in 2024, then dropped by 9.14% to $29058.0 in 2025, then decreased by 21.86% to $22707.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $22707.0, $33100.0, and $29058.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.